Heterogenous expression of endoglin marks advanced renal cancer with distinct tumor microenvironment fitness

Momoi, Yusaku; Nishida, Jun; Miyakuni, Kosuke; Kuroda, Masafumi; Kubota, Shimpei I.; Miyazono, Kohei; Ehata, Shogo

doi:10.1111/cas.15007

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it should be mentioned that c-Ski may accelerate cancer progression mainly through the suppression of TGF-β-dependent Smad signaling, and not through the suppression of BMP-dependent Smad signaling in an experimental setting. Our latest data also indicated that endoglin expression was heterogeneously upregulated in highly malignant derivatives obtained after serial transplantation of human RCC cells ( Momoi et al, 2021 ).…”

Section: Altered Expression Of Bone Morphogenetic Proteins and Their ...mentioning

confidence: 81%

Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years

Ehata

Miyazono

2022

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

Bone morphogenetic proteins (BMPs), members of the transforming growth factor-β (TGF-β) family, are multifunctional cytokines. BMPs have a broad range of functions, and abnormalities in BMP signaling pathways are involved in cancer progression. BMPs activate the proliferation of certain cancer cells. Malignant phenotypes of cancer cells, such as increased motility, invasiveness, and stemness, are enhanced by BMPs. Simultaneously, BMPs act on various cellular components and regulate angiogenesis in the tumor microenvironment. Thus, BMPs function as pro-tumorigenic factors in various types of cancer. However, similar to TGF-β, which shows both positive and negative effects on tumorigenesis, BMPs also act as tumor suppressors in other types of cancers. In this article, we review important findings published in the recent decade and summarize the pro-oncogenic functions of BMPs and their underlying mechanisms. The current status of BMP-targeted therapies for cancers is also discussed.

show abstract

Section: Altered Expression Of Bone Morphogenetic Proteins and Their ...mentioning

confidence: 81%

Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years

Ehata

Miyazono

2022

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

show abstract

Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma

Oladejo

Nguyen

Seah

et al. 2022

Cancer Immunol Immunother

View full text Add to dashboard Cite

CD105 in the progression and therapy of renal cell carcinoma

Oladejo¹,

Nguyen²,

Wood³

2023

Cancer Letters

View full text Add to dashboard Cite

Heterogenous expression of endoglin marks advanced renal cancer with distinct tumor microenvironment fitness

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 3 publications

References 34 publications

Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years

Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years

Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma

CD105 in the progression and therapy of renal cell carcinoma

Contact Info

Product

Resources

About